Form 4: CG Oncology CMO Vijay Kasturi Receives Stock Options

Chief Medical Officer Vijay Kasturi was granted 79,216 employee stock options in CG Oncology, Inc. on April 15, 2026.

Summary

• Vijay Kasturi, Chief Medical Officer of CG Oncology, Inc., was granted 79,216 employee stock options.
• The options have an exercise price of $67.68 per share.
• The options vest at a rate of 1/48th per month starting from April 15, 2026, contingent on continuous service.
• The options expire on April 14, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Vesting is subject to the Reporting Person's continuous service to the Issuer.

Future Outlook

The options vest monthly over a four-year period, incentivizing long-term retention of the Chief Medical Officer.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice to ensure leadership retention during critical clinical development phases.

Comparison to Industry Standards

• The four-year monthly vesting schedule is consistent with standard industry practices for executive compensation in mid-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Monthly vesting of options beginning May 2026.

Key Dates

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Options, Biotech